CAMP

CAMP4 is a clinical-stage (really pre-clinical) biopharma whose entire investment case rests on one unproven asset, CMP-002, an antisense oligonucleotide for SYNGAP1 disorder. The MD&A is explicit that CMP-002 is still in GLP toxicology studies and that a global Phase 1/2 trial would only begin 'as early as the second half of 2026' — so there is zero human efficacy or safety data today. The $3.50M of FY2025 revenue is collaboration/license income (largely the GSK agreement), not product sales; the P/S of 65.8x is therefore meaningless. This is a binary, single-catalyst story, and the hard rule when risk is genuinely unknowable is to stand aside.

The financials are those of a cash-burning research shell. FY2025 net loss widened to -$80.4M (from -$51.8M), net margin is -2,298% and ROE is -168.5%, with an accumulated deficit of -$292M. Operating cash burn was -$29.6M and will accelerate once the clinic opens. The one genuine positive is the balance sheet: $110M cash (+71% YoY), current assets of $114M against just $15.5M current liabilities, and modest leverage (liabilities/equity 1.47x, most of the liability jump likely tied to the new Watertown lease). At ~$30M annual operating burn that is roughly 3+ years of runway — but trial spend will shorten it, and management has already shown it will fund via dilution.